Tasigna and Pegasys drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tasigna (nilotinib hydrochloride monohydrate) and Pegasys (peginterferon alfa 2a). Common drug interactions include dyspnoea among females and electrocardiogram qt prolonged among males.

The phase IV clinical study analyzes what interactions people have when they take Tasigna and Pegasys. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

What is Pegasys?

Pegasys has active ingredients of peginterferon alfa 2a. It is often used in hepatitis c. eHealthMe is studying from 57,446 Pegasys users. Check the latest studies of Pegasys.

On Jul, 13, 2026

18 people who take Tasigna and Pegasys together, and have interactions are studied.

What are the common drug interactions of Tasigna and Pegasys, by gender? *:

female:

Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)
Duodenal stenosis (block of the first part of the small intestine)
Maternal exposure during pregnancy (use of substance during pregnancy)
Polyhydramnios (excess of amniotic fluid in the amniotic sac)
Premature delivery
Pyrexia (fever)
Weight increased
Anaemia (lack of blood)

male:

Electrocardiogram qt prolonged
Anaemia (lack of blood)
Pallor
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Pericardial effusion (fluid around the heart)
Platelet count decreased
Pleural effusion (water on the lungs)
Pyrexia (fever)
Thrombocytopenia (decrease of platelets in blood)
Aortic valve disease

What are the common drug interactions of Tasigna and Pegasys, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Velopharyngeal incompetence (malfunction of a velopharyngeal mechanism)

10-19:

n/a

20-29:

Maternal exposure during pregnancy (use of substance during pregnancy)
Polyhydramnios (excess of amniotic fluid in the amniotic sac)
Premature delivery
Duodenal stenosis (block of the first part of the small intestine)

30-39:

n/a

40-49:

Weight increased
Fatigue (feeling of tiredness)
Feeling hot
Insomnia (sleeplessness)
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Pulmonary embolism (blockage of the main artery of the lung)

50-59:

Haemoglobin decreased
Hyperthermia (body temperature greatly above normal)
Infection
Leukopenia (less number of white blood cells in blood)
Neutropenia (an abnormally low number of neutrophils)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Pallor
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Pericardial effusion (fluid around the heart)
Platelet count decreased

60+:

Carotid artery stenosis (narrowing of carotid artery)
General physical health deterioration (weak health status)
Pericarditis (inflammation of the pericardium)
Peripheral arterial occlusive disease (reproducible ischemic muscle pain)
Pyrexia (fever)

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 15 people, 83.33%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 11.11%
Stress And Anxiety: 1 person, 5.56%
Pain: 1 person, 5.56%
Neuropathy Peripheral (surface nerve damage): 1 person, 5.56%
Leukocytosis (increased white blood cells): 1 person, 5.56%
Itching: 1 person, 5.56%
High Blood Cholesterol: 1 person, 5.56%
Gout (uric acid crystals building up in the body): 1 person, 5.56%
Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Tasigna and Pegasys?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously